4004 NAD kinase beta sandwich domain-like
Ligands and drugs
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
ClassyFire chemical superclasses of the ligands bound by this X-group's proteins, from DrugDomain annotations.
The raw number of superclasses rises with the number of proteins sampled; the per-20 value compares X-groups at equal depth.
| Superclass | Proteins | Expected | 0.25×observed / expected4× | Ratio | Significance |
|---|---|---|---|---|---|
| Homogeneous metal compounds | 6 | 5.8 | 1.03× | q = 1.00 | |
| Organic nitrogen compounds | 1 | 0.4 | 2.65× | not tested | |
| Nucleosides, nucleotides, and analogues | 8 | 3.3 | 2.45× | not tested | |
| Homogeneous non-metal compounds | 3 | 2.6 | 1.18× | not tested | |
| Benzenoids | 1 | 0.9 | 1.16× | not tested | |
| Organoheterocyclic compounds | 1 | 1.8 | 0.55× | not tested |
Unit: a protein (UniProt accession) with a ligand-binding domain in this X-group, counted once per superclass. Expected counts use each superclass's frequency across all ligand-binding X-groups; significance is Fisher's exact test with Benjamini–Hochberg correction. Buffers and crystallization additives are excluded. ECOD v295.2; the method follows the ECOD 2027 update, whose published figures used a slightly different artifact filter.
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB03461 | NAP | Nicotinamide adenine dinucleotide phosphate | 12 |
| DB14128 | NAD | Nadide | 8 |
| DB00171 | ATP | ATP | 4 |
| DB16833 | ADP | Adenosine disphosphate | 3 |
| DB00157 | NAI | NADH | 2 |
| DB02282 | MTA | 5'-S-methyl-5'-thioadenosine | 2 |
| DB03203 | SQS | Sphingosine | 2 |
| DB00144 | — | Phosphatidyl serine | 1 |
| DB12764 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 22 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 12 |
| NAP | NADP NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE | 12 |
| UUL | 4-{[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino}phenol | 12 |
| 5A8 | 5'-azido-5'-deoxy-8-[(2-{[2-(1H-indol-3-yl)ethyl]amino}-2-oxoethyl)sulfanyl]adenosine | 4 |
| 5A9 | 5'-azido-8-[(2-{[2-(3-bromophenyl)ethyl]amino}-2-oxoethyl)sulfanyl]-5'-deoxyadenosine | 4 |
| 5AG | 5'-azido-5'-deoxy-8-[(2-{[2-(3-ethynylphenyl)ethyl]amino}-2-oxoethyl)sulfanyl]adenosine | 4 |
| 5AJ | 5'-azido-8-[(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}-2-oxoethyl)sulfanyl]-5'-deoxyadenosine | 4 |
| 5AK | 8-[(2-{[2-(3-bromophenyl)ethyl]amino}-2-oxoethyl)sulfanyl]adenosine | 4 |
| 5AQ | 8-({2-oxo-2-[(2-phenylethyl)amino]ethyl}sulfanyl)adenosine | 4 |
| ATP | ADENOSINE-5'-TRIPHOSPHATE | 4 |
| CAmetal | CALCIUM ION | 4 |
| IOD | IODIDE ION | 4 |
| UNX | UNKNOWN ATOM OR ION | 4 |
| 1V2 | (2R,4S)-1-[2-(4-{[4-(3,4-dichlorophenyl)-1,3-thiazol-2-yl]amino}phenyl)ethyl]-2-(hydroxymethyl)piperidin-4-ol | 3 |
| 5NB | 5'-amino-8-bromo-5'-deoxyadenosine | 2 |
| ADP | ADENOSINE-5'-DIPHOSPHATE | 2 |
| DTA | (2S,3S,4R,5R,2'S,3'S,4'R,5'R)-2,2'-[DITHIOBIS(METHYLENE)]BIS[5-(6-AMINO-9H-PURIN-9-YL)TETRAHYDROFURAN-3,4-DIOL] | 2 |
| GYR | {(2R)-1-[4-({3-METHYL-5-[(PHENYLSULFONYL)METHYL]PHENOXY}METHYL)BENZYL]PYRROLIDIN-2-YL}METHANOL | 2 |
| MTA | 5'-DEOXY-5'-METHYLTHIOADENOSINE | 2 |